Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Review

MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers

Authors: Benjamin L Jackson, Anna Grabowska, Hari L Ratan

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

This non-systematic review article aims to summarise the progress made in understanding the functional consequences of microRNA (miRNA) dysregulation in prostate cancer development, and the identification of potential miRNA targets as serum biomarkers for diagnosis or disease stratification.

Results

A number of miRNAs have been shown to influence key cellular processes involved in prostate tumourigenesis, including apoptosis-avoidance, cell proliferation and migration and the androgen signalling pathway. An overlapping group of miRNAs have shown differential expression in the serum of patients with prostate cancer of varying stages compared with unaffected individuals. The majority of studies thus far however, involve small numbers of patients and have shown variable and occasionally conflicting results

Conclusion

MiRNAs show promise as potential circulating biomarkers in prostate cancer, but larger prospective studies are required to validate particular targets and better define their clinical utility.
Literature
1.
Lee RC, Feinbaum RL, Ambros V: The C-elegans heterochronic gene Lin-4 encodes small rnas with antisense complementarity to Lin-14. Cell. 1993, 75 (5): 843-854. 10.1016/0092-8674(93)90529-Y.CrossRefPubMed
2.
3.
4.
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18 (10): 997-1006. 10.1038/cr.2008.282.CrossRefPubMed
5.
6.
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008, 105 (30): 10513-10518. 10.1073/pnas.0804549105.CrossRef
7.
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144 (5): 646-674. 10.1016/j.cell.2011.02.013.CrossRefPubMed
8.
Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T: MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011, 59 (5): 671-681. 10.1016/j.eururo.2011.01.044.CrossRefPubMed
9.
Amir S, Ma AH, Shi XB, Xue L, Kung HJ, White RWd: Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer. PLoS One. 2013, 8: 4-CrossRef
10.
Shi X-B, Xue L, Ma A-H, Tepper CG, Kung H-J, White RW: miR-125b promotes growth of prostate cancer xenograft tumor through targeting Pro-apoptotic genes. Prostate. 2011, 71 (5): 538-549. 10.1002/pros.21270.CrossRefPubMed
11.
Aqeilan RI, Calin GA, Croce CM: miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2010, 17 (2): 215-220. 10.1038/cdd.2009.69.CrossRefPubMed
12.
Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C, Bartucci M, Muto G, Peschle C, De Maria R: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008, 14 (11): 1271-1277. 10.1038/nm.1880.CrossRefPubMed
13.
Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, Li Y: MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene. 2008, 27 (31): 4373-4379. 10.1038/onc.2008.72.CrossRefPubMed
14.
Yang CH, Yue J, Fan M, Pfeffer LM: IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res. 2010, 70 (20): 8108-8116. 10.1158/0008-5472.CAN-10-2579.CrossRefPubMedPubMedCentral
15.
Attwooll C, Denchi EL, Helin K: The E2F family: specific functions and overlapping interests. Embo J. 2004, 23 (24): 4709-4716. 10.1038/sj.emboj.7600481.CrossRefPubMedPubMedCentral
16.
Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, Ferbeyre G, Chartrand P: An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 2007, 282 (4): 2135-2143. 10.1074/jbc.M608939200.CrossRefPubMed
17.
Pesta M, Klecka J, Kulda V, Topolcan O, Hora M, Eret V, Ludvikova M, Babjuk M, Novak K, Stolz J, Holubec L: Importance of miR-20a expression in prostate cancer tissue. Anticancer Res. 2010, 30 (9): 3579-3583.PubMed
18.
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008, 68 (15)): 6162-6170.CrossRefPubMedPubMedCentral
19.
Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, Valdagni R, Daidone MG, Zaffaroni N: miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase C epsilon. Cancer Res. 2009, 69 (6): 2287-2295. 10.1158/0008-5472.CAN-08-2894.CrossRefPubMed
20.
Menges CW, Altomare DA, Testa JR: FAS-Associated Factor 1 (FAF1): Diverse functions and implications for oncogenesis. Cell Cycle. 2009, 8 (16): 2528-2534. 10.4161/cc.8.16.9280.CrossRefPubMedPubMedCentral
21.
Qin WM, Shi Y, Zhao BT, Yao CG, Jin L, Ma JX, Jin YX: miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One. 2010, 5: 2-
22.
Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO, Saini S, Majid S, Liu J, Khatri G, Tanaka Y, Dahiya R: The functional significance of microRNA-145 in prostate cancer. Br J Cancer. 2010, 103 (2): 256-264. 10.1038/sj.bjc.6605742.CrossRefPubMedPubMedCentral
23.
Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ: Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (Baltimore Md: 1950). 2002, 168 (3): 1356-1361. 10.4049/jimmunol.168.3.1356.CrossRef
24.
Taddei ML, Giannoni E, Fiaschi T, Chiarugi P: Anoikis: an emerging hallmark in health and diseases. J Pathol. 2012, 226 (2): 380-393. 10.1002/path.3000.CrossRefPubMed
25.
Ong CHP, Bateman A: Progranulin (Granulin-epithelin precursor, PC-cell derived growth factor, Acrogranin) in proliferation and tumorigenesis. Histol Histopathol. 2003, 18 (4): 1275-1288.PubMed
26.
Monami G, Emiliozzi V, Bitto A, Lovat F, Xu SQ, Goldoni S, Fassan M, Serrero G, Gomella LG, Baffa R, Iozzo RV, Morrione A: Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth. Am J Pathol. 2009, 174 (3): 1037-1047. 10.2353/ajpath.2009.080735.CrossRefPubMedPubMedCentral
27.
Wang WX, Kyprianou N, Wang XW, Nelson PT: Dysregulation of the mitogen granulin in human cancer through the miR-15/107 microRNA gene group. Cancer Res. 2010, 70 (22): 9137-9142. 10.1158/0008-5472.CAN-10-1684.CrossRefPubMedPubMedCentral
28.
Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Naya Y, Ichikawa T, Seki N: Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol. 2011, 38 (4): 1093-1101.PubMed
29.
Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z, Li P, Zhang W, Wu H, Feng N, Wang Z, Hua L, Wang X: miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem. 2011, 350 (1–2): 207-213.CrossRefPubMed
30.
Tao J, Wu DY, Xu B, Qian WC, Li PC, Lu Q, Yin CJ, Zhang W: microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep. 2012, 27 (6): 1967-1975.PubMed
31.
Xu B, Wang N, Wang X, Tong N, Shao N, Tao J, Li P, Niu X, Feng N, Zhang L, Hua L, Wang Z, Chen M: MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate. 2012, 72 (11): 1171-1178. 10.1002/pros.22466.CrossRefPubMed
32.
33.
Gandellini P, Profumo V, Casamichele A, Fenderico N, Borrelli S, Petrovich G, Santilli G, Callari M, Colecchia M, Pozzi S, De Cesare M, Folini M, Valdagni R, Mantovani R, Zaffaroni N: miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ. 2012, 19 (11): 1750-1760. 10.1038/cdd.2012.56.CrossRefPubMedPubMedCentral
34.
Peng X, Guo W, Liu T, Wang X, Tu X, Xiong D, Chen S, Lai Y, Du H, Chen G, Liu G, Tang Y, Huang S, Zou X: Identification of miRs-143 and-145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One. 2011, 6: 5-
35.
Huang S, Guo W, Tang Y, Ren D, Zou X, Peng X: miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep. 2012, 28 (5): 1831-1837.PubMed
36.
Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB: MicroRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol Cancer Ther. 2012, 11 (5): 1166-1173. 10.1158/1535-7163.MCT-12-0100.CrossRefPubMed
37.
Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT, Lupold SE: miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009, 69 (18): 7165-7169. 10.1158/0008-5472.CAN-09-1448.CrossRefPubMedPubMedCentral
38.
Li T, Li RS, Li YH, Zhong S, Chen YY, Zhang CM, Hu MM, Shen ZJ: miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol. 2012, 187 (4): 1466-1472. 10.1016/j.juro.2011.11.082.CrossRefPubMed
39.
Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Janne OA, Seppala J, Lahdesmaki H, Tammela TLJ, Visakorpi T: Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene. 2012, 31 (41): 4460-4471. 10.1038/onc.2011.624.CrossRefPubMed
40.
Fletcher CE, Dart DA, Sita-Lumsden A, Cheng H, Rennie PS, Bevan CL: Androgen-regulated processing of the oncomir MiR-27a, which targets prohibitin in prostate cancer. Hum Mol Genet. 2012, 21 (14): 3112-3127. 10.1093/hmg/dds139.CrossRefPubMed
41.
Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen PJ, Latonen LM, Kallioniemi OP, Jenster G, Visakorpi T: Androgen regulation of micro-RNAs in prostate cancer. Prostate. 2011, 71 (6): 604-614. 10.1002/pros.21276.CrossRefPubMed
42.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature. 2005, 435 (7043): 834-838. 10.1038/nature03702.CrossRefPubMed
43.
Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P: The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009, 69 (8): 3356-3363. 10.1158/0008-5472.CAN-08-4112.CrossRefPubMedPubMedCentral
44.
Spahn M, Kneitz S, Scholz CJ, Stenger N, Rudiger T, Strobel P, Riedmiller H, Kneitz B: Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer. 2010, 127 (2): 394-403.PubMed
45.
Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ: miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem. 2009, 284 (37): 24696-24704. 10.1074/jbc.M109.030098.CrossRefPubMedPubMedCentral
46.
Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, EVere White RW, Kung HJ, Evans CP, Gao AC: MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem. 2012, 287 (2): 1527-1537. 10.1074/jbc.M111.278705.CrossRefPubMed
47.
Mulholland DJ, Dedhar S, Wu H, Nelson CC: PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene. 2006, 25 (3): 329-337. 10.1038/sj.onc.1209020.CrossRefPubMed
48.
Sarker D, Reid AH, Yap TA, de Bono JS: Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2009, 15 (15): 4799-4805. 10.1158/1078-0432.CCR-08-0125.CrossRef
49.
Tian L, Fang YX, Xue JL, Chen JZ: Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro. PLoS One. 2013, 8 (9): e75885-10.1371/journal.pone.0075885.CrossRefPubMedPubMedCentral
50.
Wu Z, He B, He J, Mao X: Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer. Prostate. 2013, 73 (6): 596-604. 10.1002/pros.22600.CrossRefPubMed
51.
Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, Rameh L, Loda M, Pandolfi PP: Identification of the miR-106b ~ 25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal. 2010, 3 (117): ra29-CrossRefPubMedPubMedCentral
52.
Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010, 465 (7301): 1033-1038. 10.1038/nature09144.CrossRefPubMedPubMedCentral
53.
Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez-Billalabeitia E, Egia A, Shaffer DR, Carver B, Liu XS, Taulli R, Kuo WP, Nardella C, Signoretti S, Cordon-Cardo C, Gerald WL, Pandolfi P: Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet. 2013, 45 (7): 739-746. 10.1038/ng.2654.CrossRefPubMedPubMedCentral
54.
Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Sci (New York NY). 2005, 310 (5748): 644-648. 10.1126/science.1117679.CrossRef
55.
Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal R, Gazit E, Rotter V, Berger R: TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS One. 2011, 6 (7): e21650-10.1371/journal.pone.0021650.CrossRefPubMedPubMedCentral
56.
Kim J, Wu L, Zhao JC, Jin HJ, Yu J: TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. Oncogene. 2014, 33 (44): 5183-5192. 10.1038/onc.2013.461.CrossRefPubMed
57.
Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, DeVere White RW, Kung HJ: miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene. 2014, 33 (19): 2495-2503. 10.1038/onc.2013.200.CrossRefPubMed
58.
Gordanpour A, Stanimirovic A, Nam RK, Moreno CS, Sherman C, Sugar L, Seth A: miR-221 Is down-regulated in TMPRSS2:ERG fusion-positive prostate cancer. Anticancer Res. 2011, 31 (2): 403-410.PubMedPubMedCentral
59.
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002, 419 (6907): 624-629. 10.1038/nature01075.CrossRefPubMed
60.
Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M, Schulz WA: Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Therapy. 2007, 6 (9): 1403-1412.CrossRef
61.
Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM: An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010, 17 (5): 443-454. 10.1016/j.ccr.2010.03.018.CrossRefPubMedPubMedCentral
62.
Börno ST, Fischer A, Kerick M, Fälth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, Isau M, Röhr C, Wunderlich A, Timmermann B, Claus R, Plass C, Graefen M, Simon R, Demichelis F, Rubin MA, Sauter G, Schlomm T, Sültmann H, Lehrach H, Schweiger MR: Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov. 2012, 2 (11): 1024-1035. 10.1158/2159-8290.CD-12-0041.CrossRefPubMed
63.
Cao P, Deng Z, Wan M, Huang W, Cramer SD, Xu J, Lei M, Sui G: MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer. 2010, 9: 108-10.1186/1476-4598-9-108.CrossRefPubMedPubMedCentral
64.
65.
Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B: Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One. 2009, 4: 7-CrossRef
66.
Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stoppler H, Simko J, Hilton JF, Carroll P, Blelloch R: Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011, 71 (2): 550-560. 10.1158/0008-5472.CAN-10-1229.CrossRefPubMed
67.
Agaoglu FY, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, Gezer U: Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biol. 2011, 32 (3): 583-588. 10.1007/s13277-011-0154-9.CrossRef
68.
Gonzales JC, Fink LM, Goodman OB, Symanowski JT, Vogelzang NJ, Ward DC: Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer. 2011, 9 (1): 39-45. 10.1016/j.clgc.2011.05.008.CrossRefPubMed
69.
Zhang H-L, Yang L-F, Zhu Y, Yao X-D, Zhang S-L, Dai B, Zhu Y-P, Shen Y-J, Shi G-H, Ye D-W: Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate. 2011, 71 (3): 326-331. 10.1002/pros.21246.CrossRefPubMed
70.
Brase JC, Johannes M, Schlomm T, Faelth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sueltmann H: Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011, 128 (3): 608-616. 10.1002/ijc.25376.CrossRefPubMed
71.
Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, Chi KN, Marshall VR, Tilley WD, Butler LM: Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer. 2012, 131 (3): 652-661. 10.1002/ijc.26405.CrossRefPubMed
72.
Selth LA, Townley SL, Bert AG, Stricker PD, Sutherland PD, Horvath LG, Goodall GJ, Butler LM, Tilley WD: Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer. 2013, 109 (3): 641-650. 10.1038/bjc.2013.369.CrossRefPubMedPubMedCentral
73.
Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC: Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012, 106 (4): 768-774. 10.1038/bjc.2011.595.CrossRefPubMedPubMedCentral
74.
Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L: Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015, 67 (1): 33-41. 10.1016/j.eururo.2014.07.035.CrossRefPubMed
75.
Lazaro-Ibanez E, Sanz-Garcia A, Visakorpi T, Escobedo-Lucea C, Siljander P, Ayuso-Sacido A, Yliperttula M: Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes. Prostate. 2014, 74 (14): 1379-1390. 10.1002/pros.22853.CrossRefPubMedPubMedCentral
76.
Nguyen HCN, Xie W, Yang M, Hsieh C-L, Drouin S, Lee G-SM, Kantoff PW: Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate. 2013, 73 (4): 346-354. 10.1002/pros.22572.CrossRefPubMed
77.
Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM, Yang J: A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 2012, 72 (13): 1443-1452. 10.1002/pros.22495.CrossRefPubMed
78.
Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, Santella RM: Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012, 72 (13): 1469-1477. 10.1002/pros.22499.CrossRefPubMedPubMedCentral
79.
Hao Y, Zhao Y, Zhao X, He C, Pang X, Wu TC, Califano JA, Gu X: Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling. Cancer Investig. 2011, 29 (4): 318-324. 10.3109/07357907.2011.554477.CrossRef
80.
Sun T, Yang M, Chen SY, Balk S, Pomerantz M, Hsieh CL, Brown M, Lee GSM, Kantoff PW: The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate. 2012, 72 (10): 1093-1103. 10.1002/pros.22456.CrossRefPubMed
81.
Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010, 126 (5): 1166-1176.PubMed
82.
Szczyrba J, Nolte E, Wach S, Kremmer E, Stohr R, Hartmann A, Wieland W, Wullich B, Grasser FA: Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma. Mol Cancer Res. 2011, 9 (6): 791-800. 10.1158/1541-7786.MCR-10-0573.CrossRefPubMed
Metadata
Title
MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers
Authors
Benjamin L Jackson
Anna Grabowska
Hari L Ratan
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-930

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Multiple pregnancies, hepatitis C, and risk for hepatocellular carcinoma in Egyptian women

Research article

Tongue carcinoma infrequently harbor common actionable genetic alterations

Research article

MicroRNA-26b inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting USP9X

Research article

MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression

Research article

Expression of E-cadherin and β-catenin in basaloid and conventional squamous cell carcinoma of the oral cavity: are potential prognostic markers?

Study protocol

Dexamethasone for the prevention of a pain flare after palliative radiotherapy for painful bone metastases: a multicenter double-blind placebo-controlled randomized trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits